The South San Francisco company intends to use the funding to launch its pivotal trial for its blood-based colorectal cancer screening and submit its test for parallel review for CMS coverage.
The company, led by a Gilead Sciences veteran, plans to use the platform to find drugs that go after "undruggable" targets.
The future looks bright for the integrated specialty pharmacy model – for health systems, providers, and most importantly, for patients.
Polaris Partners led the Series B round, and Ignition Partners, Osage University Partners, Mindset Ventures and UL Ventures also participated.
The company will focus on what it called a previously unexplored field in drug discovery, membrane-less cell organelles called biomolecular condensates
The company hopes to start IND-enabling studies and clinical trials next year of orally available drugs in a class currently dominated by injected monoclonal antibodies.
The funding comes as competition for the Medicare population by startup and growth-stage companies intensifies, not only from other technology-led healthcare organizations like Iora but also from the likes of CVS Health and more established companies like CareMore.
Executives from Imagine360, Verily, BrightInsight, Lantern, and Rhapsody shared their approaches to reducing healthcare costs and facilitating digital transformation.
Biology is being digitized, machines are learning and Big Data is overhauling the way we understand the health of populations and individuals. It's a fundamental shift that's also impacting the financing and formation of startups.
Robert J. Beall, president of the Cystic Fibrosis Foundation, spoke to a small group of venture capitalists and biosciences entrepreneurs in San Francisco Sunday night, highlighting the importance of having patients’ voices heard when it comes to drug research. Beall, who created the model for “venture philanthropy,” said that the $3.3 billon the foundation received […]